ZA201905470B - Method for generating t cells progenitors - Google Patents

Method for generating t cells progenitors

Info

Publication number
ZA201905470B
ZA201905470B ZA2019/05470A ZA201905470A ZA201905470B ZA 201905470 B ZA201905470 B ZA 201905470B ZA 2019/05470 A ZA2019/05470 A ZA 2019/05470A ZA 201905470 A ZA201905470 A ZA 201905470A ZA 201905470 B ZA201905470 B ZA 201905470B
Authority
ZA
South Africa
Prior art keywords
generating
cells
cells progenitors
progenitors
stemregenin
Prior art date
Application number
ZA2019/05470A
Other languages
English (en)
Inventor
Andre Isabelle
CAVAZZANA Marina
Ma Kuiying
Tchen John
Tayebeh-Shabi Soheili
Moirangthem Ranjita Devi
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Univ Paris Descartes
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Univ Paris Descartes, Inst Nat Sante Rech Med filed Critical Hopitaux Paris Assist Publique
Publication of ZA201905470B publication Critical patent/ZA201905470B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/125Stem cell factor [SCF], c-kit ligand [KL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/145Thrombopoietin [TPO]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2307Interleukin-7 (IL-7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/25Tumour necrosing factors [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/26Flt-3 ligand (CD135L, flk-2 ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/42Notch; Delta; Jagged; Serrate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/50Proteins
    • C12N2533/52Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
ZA2019/05470A 2017-02-13 2019-08-19 Method for generating t cells progenitors ZA201905470B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Publications (1)

Publication Number Publication Date
ZA201905470B true ZA201905470B (en) 2024-12-18

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/05470A ZA201905470B (en) 2017-02-13 2019-08-19 Method for generating t cells progenitors

Country Status (17)

Country Link
US (5) US20200046767A1 (https=)
EP (2) EP3580330B1 (https=)
JP (2) JP7164798B2 (https=)
KR (1) KR102666158B1 (https=)
CN (1) CN110506110B (https=)
AU (1) AU2018217404B2 (https=)
BR (1) BR112019016672A8 (https=)
CA (1) CA3053294A1 (https=)
DK (1) DK3580330T3 (https=)
ES (1) ES2931530T3 (https=)
HU (1) HUE060548T2 (https=)
IL (1) IL268641B2 (https=)
MA (1) MA47541A (https=)
PL (1) PL3580330T3 (https=)
PT (1) PT3580330T (https=)
WO (1) WO2018146297A1 (https=)
ZA (1) ZA201905470B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors
WO2019067811A1 (en) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota METHODS OF MANUFACTURING, EXPANDING AND USING HUMAN PROGENITOR CELL
JP2021514185A (ja) 2018-02-14 2021-06-10 サニーブルック リサーチ インスティチュート T細胞系列の細胞を発生させるための方法
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
AU2020265737A1 (en) * 2019-05-01 2021-12-02 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
AU2020301413A1 (en) * 2019-06-24 2022-02-10 Children's Hospital Los Angeles BCL11B overexpression to enhance human thymopoiesis T cell function
EP4058562A4 (en) * 2019-11-14 2023-12-20 Zandstra, Peter William MEDIA FORMULATIONS AND PROCESSES FOR PRODUCING PROGENITOR T CELLS
WO2021200901A1 (ja) * 2020-03-31 2021-10-07 国立大学法人京都大学 T前駆細胞の製造方法
EP4251651A4 (en) 2020-11-30 2025-07-09 Cho Pharma Inc ANTIBODIES FOR CELL ENRICHMENT
CN117377756A (zh) * 2021-03-05 2024-01-09 菲克特生物科学股份有限公司 工程化免疫细胞疗法
EP4347793A1 (en) * 2021-05-25 2024-04-10 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
EP4426319A1 (en) * 2021-11-04 2024-09-11 APHP (Assistance Publique - Hôpitaux de Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
WO2024156066A1 (en) 2023-01-27 2024-08-02 Notch Therapeutics (Canada), Inc. Method for generating t cell lineage populations from stem/progenitor cells
KR20250152088A (ko) * 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Cd7+cd34−lin−造血細胞を単離し、使用する方法
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
BRPI0919020B8 (pt) 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
JP5756017B2 (ja) 2008-11-07 2015-07-29 サニーブルック ヘルス サイエンシズ センター ヒト前駆t細胞
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
US20130095079A1 (en) 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CA2858069C (en) * 2011-12-08 2020-02-11 Novartis Ag Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20150352180A1 (en) 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2015099134A1 (ja) 2013-12-26 2015-07-02 アストリム株式会社 再構成されたt細胞レセプター遺伝子を有する多能性幹細胞由来のt前駆細胞を用いる免疫細胞療法
KR20160145802A (ko) 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したt細胞の自動生成法
EP3191596B1 (en) 2014-09-11 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Lentiviral vector for treating hemoglobin disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
CA2989858A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
JP7049261B2 (ja) 2016-04-08 2022-04-06 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント 幹細胞および/または前駆細胞からt前駆細胞を作製する方法ならびに該t前駆細胞の使用
IL268641B2 (en) * 2017-02-13 2024-10-01 Assist Publique Hopitaux Paris Aphp Method for generating t cells progenitors

Also Published As

Publication number Publication date
IL268641A (en) 2019-10-31
AU2018217404A2 (en) 2019-09-19
BR112019016672A2 (pt) 2020-04-14
US20200046767A1 (en) 2020-02-13
US20200390817A1 (en) 2020-12-17
JP2020513844A (ja) 2020-05-21
JP2022185024A (ja) 2022-12-13
AU2018217404A1 (en) 2019-09-05
MA47541A (fr) 2019-12-18
WO2018146297A1 (en) 2018-08-16
DK3580330T3 (da) 2022-12-05
HUE060548T2 (hu) 2023-03-28
EP4067482A1 (en) 2022-10-05
US11426430B2 (en) 2022-08-30
IL268641B1 (en) 2024-06-01
IL268641B2 (en) 2024-10-01
RU2019125600A3 (https=) 2021-11-03
EP3580330B1 (en) 2022-08-31
US11642376B2 (en) 2023-05-09
US20230293586A1 (en) 2023-09-21
PT3580330T (pt) 2022-12-06
CN110506110A (zh) 2019-11-26
US11638723B2 (en) 2023-05-02
CN110506110B (zh) 2024-09-06
EP3580330A1 (en) 2019-12-18
CA3053294A1 (en) 2018-08-16
ES2931530T3 (es) 2022-12-30
KR20190117550A (ko) 2019-10-16
RU2019125600A (ru) 2021-03-15
BR112019016672A8 (pt) 2022-11-22
US20210169934A1 (en) 2021-06-10
KR102666158B1 (ko) 2024-05-16
AU2018217404B2 (en) 2024-03-28
PL3580330T3 (pl) 2023-01-16
JP7164798B2 (ja) 2022-11-02
US20210169935A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
ZA201905470B (en) Method for generating t cells progenitors
EP4653536A3 (en) Compositions and methods for enhanced gene expression
MX2016013938A (es) Metodo y aparato para incrementar el contenido de medios.
MX2025002021A (es) Inmunoterapia con receptores de antigeno quimerico y uso de la misma
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
MY204838A (en) Concept for generating an enhanced sound-field description or a modified sound field description using a depth-extended dirac technique or other techniques
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
MY189778A (en) Method for producing retinal pigment epithelial cells
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
MY201573A (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
WO2019101227A3 (en) System and method for implementing blockchain-based digital certificates
MX2022013114A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
MX2016001986A (es) Metodo para preparar rebaudiosido m mediante el uso de un metodo con enzima.
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
AU2018308587A1 (en) Method for the preparation of ammonia synthesis gas
MX2019010575A (es) Metodo para producir anticuerpos multiespecificos.
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
MX2014012838A (es) Composiciones para cultivo celular y metodos para la produccion de polipetidos.
GB2500342A (en) System and methods for integrating and using information relating to a complex process
MX2021007433A (es) Metodos de cultivo de una celula de mamifero.
TW201612308A (en) Collector architecture layout design
SG11201806642QA (en) Heat storage particles, method for producing same, and heat storage material
EP4058597A4 (en) SYSTEMS, METHODS AND COMPOSITIONS FOR GENERATING MULTI-OMICS INFORMATION FROM SINGLE CELLS
EA201791233A1 (ru) Материал стволовых клеток и способ его получения